BriSTAR Immunotech
PrivateLast Round
Series C
Jul 6, 2026
Total Funding Raised
$65.5M
Company Overview
BriSTAR Immunotech operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series C round in July 2026.
BriSTAR Immunotech is a clinical-stage biotechnology company that develops engineered T-cell immunotherapy products for cancer and autoimmune diseases using its proprietary STAR-T and enTCR-T technology platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BriSTAR Immunotech Comparables
Compare BriSTAR Immunotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IASO Bio | 81% | |
| BioSyngen | 81% | |
| AstraZeneca | 81% |
For institutional investors. Book with your work email.
BriSTAR Immunotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 6, 2026 | ||||
| Series B Extension | Jul 18, 2022 | ||||
| Series B | Oct 11, 2021 | ||||
| Series A Extension | Jan 1, 2020 |
For institutional investors. Book with your work email.
BriSTAR Immunotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Beijing Chang Development | Series B |
| Loyal Valley Capital | Series C |
| Shenzhen Sangel Venture Capital | Series B |
| Highlight Capital | Series B |
| Daoyuan Capital | Series B |
| Qifu Capital | Series A, Angel, Pre Seed |
| Hankang Capital | Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 18, 2022
Completed a Series B Extension round of funding.
- Oct 11, 2021
$31M round led by 华创资本
For institutional investors. Book with your work email.
BriSTAR Immunotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BriSTAR Immunotech's valuation, stock price, and market status.
Is BriSTAR Immunotech a public or private company?
BriSTAR Immunotech is a private company.
What is the current stock price of BriSTAR Immunotech?
BriSTAR Immunotech is a private company, so its shares have no public market price. Caplight tracks BriSTAR Immunotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BriSTAR Immunotech worth (valuation)?
Valuation information for BriSTAR Immunotech is not publicly available.
Can I buy BriSTAR Immunotech stock?
BriSTAR Immunotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BriSTAR Immunotech's last funding round?
BriSTAR Immunotech's most recent funding round was Series C on July 6, 2026.
Who are the main investors in BriSTAR Immunotech?
Key investors in BriSTAR Immunotech include Loyal Valley Capital, Hankang Capital, 华创资本.
Will BriSTAR Immunotech IPO soon?
No public IPO plans have been announced for BriSTAR Immunotech.
How can I track BriSTAR Immunotech secondary market activity?
Caplight tracks bids, offers, and trades in BriSTAR Immunotech's shares on secondary markets.